ArticleRMD open2026
Impact of ANCA specificity on risk of cardiovascular events and death in ANCA-associated vasculitis.
Article in RMD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to investigate the relationship between antineutrophil cytoplasmic antibodies (ANCA) specificity and the risk of major adverse cardiovascular events (MACE) in patients with ANCA-associated vasculitis (AAV).
methodsWe conducted a retrospective study using the ANCA-associated vasculitis Toulouse cohort. The incidence of MACE, defined as myocardial infarction (MI) and/or stroke and/or all-cause death, was compared among patients according to their ANCA specificity. We also applied Cox regression models adjusted for traditional cardiovascular risk factors, age and sex to assess the risk of MI, stroke and MACE.
resultsA total of 402 patients were included, of whom 166 (41%) had antiproteinase 3 (anti-PR3) ANCA and 236 (59%) had antimyeloperoxidase (anti-MPO) ANCA. We identified 78 MACE during the follow-up period, including 15 MIs, 12 strokes and 62 deaths. The incidence rate of MACE in the ANCA+anti-PR3+ group was 21.4 per 1000 patient-years compared with 33.1 per 1000 patient-years in the ANCA+anti-MPO+ group (p=0.036). The time elapsed between the diagnosis of AAV and MACE occurrence was significantly shorter in the ANCA+anti-MPO+ group. The Cox regression model found that patients with anti-MPO ANCA tend to present more MACE, but the association was not statistically significant (HR 1.62; 95% CI 0.98 to 2.66; p=0.06). An association was found between the presence of anti-PR3 ANCA and a lower risk of strokes (HR 0.61; 95% CI 0.37 to 0.99; p=0.049) and none with the risk of MI.
conclusionPatients with anti-MPO ANCA appear to be at a higher risk of a composite MACE-all-cause mortality outcome than patients with anti-PR3 ANCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.